Anchored in work undertaken and IP issued to University of New Mexico Health Center and the Alburqueque Department of Veteran's Affairs Azano Pharmaceuticals had been organized around harnessing the power of small molecules and proteins to develop innovative therapies. In addition to the commercialization of the GPER ligands, Azano had been actively pursuing the development of a C-reactive protein (CRP) derivative to treat Systemic Lupus Erythematosus (SLE) and other autoimmune diseases. As on mid-teens, wenbiste is non functional and principals of the firm appear to have relocated elsewhere suggesting the firm has dicontinued perioations.
